Contact
searchSearch
HMP Global
Login
Donald Moore, PharmD
Videos
Dexamethasone vs Tocilizumab for CRS Management With Talquetamab
04/08/2026
Donald Moore, PharmD
Donald Moore, PharmD, discusses results from a multicenter retrospective analysis comparing dexamethasone and tocilizumab for management of CRS in patients receiving talquetamab for relapsed/refractory multiple myeloma.
Donald Moore, PharmD, discusses results from a multicenter retrospective analysis comparing dexamethasone and tocilizumab for management of CRS in patients receiving talquetamab for relapsed/refractory multiple myeloma.
Donald Moore, PharmD, discusses...
04/08/2026
Oncology
Sarah Proffitt, PharmD
Videos
Building Real-World Evidence Through the HERO Consortium
04/08/2026
Sarah Proffitt, PharmD
Sarah Proffitt, PharmD, discusses the development and impact of the HERO Consortium, a pharmacist-led, multicenter research collaborative.
Sarah Proffitt, PharmD, discusses the development and impact of the HERO Consortium, a pharmacist-led, multicenter research collaborative.
Sarah Proffitt, PharmD,...
04/08/2026
Oncology
News
Administration of Live MMR Vaccine Appears Safe in Selected Post-Transplant Patients With Multiple Myeloma
03/26/2026
Emily Estrada
Results from a retrospective study suggest that measles-mumps-rubella vaccination appears safe in post-transplantation patients with multiple myeloma receiving daratumumab maintenance.
Results from a retrospective study suggest that measles-mumps-rubella vaccination appears safe in post-transplantation patients with multiple myeloma receiving daratumumab maintenance.
Results from a retrospective...
03/26/2026
Oncology
Kirollos Hanna, PharmD
Videos
Darolutamide Plus ADT Improves Outcomes in Metastatic Hormone-Sensitive Prostate Cancer
03/25/2026
Kirollos S. Hanna, PharmD, BCPS, BCOP, FACC
Kirollos Hanna, PharmD, discusses results from the phase 3 ARANOTE trial evaluating darolutamide plus ADT in metastatic hormone-sensitive prostate cancer.
Kirollos Hanna, PharmD, discusses results from the phase 3 ARANOTE trial evaluating darolutamide plus ADT in metastatic hormone-sensitive prostate cancer.
Kirollos Hanna, PharmD,...
03/25/2026
Oncology
News
Imlunestrant Demonstrates Favorable Safety Alone and With Abemaciclib in Advanced Breast Cancer
03/24/2026
Emily Estrada
Detailed safety findings from the phase 3 EMBER-3 trial further support imlunestrant alone or in combination with abemaciclib in patients with ER-positive, HER2-negative advanced breast cancer.
Detailed safety findings from the phase 3 EMBER-3 trial further support imlunestrant alone or in combination with abemaciclib in patients with ER-positive, HER2-negative advanced breast cancer.
Detailed safety findings from...
03/24/2026
Oncology
News
Early Dose Reductions Improve Persistence With Adjuvant Abemaciclib in High-Risk Early Breast Cancer
03/24/2026
Emily Estrada
Real-world data from the US Flatiron Health Research Database demonstrate that most patients with HR-positive, HER2-negative early breast cancer remain on adjuvant abemaciclib at 6 months, with dosing strategies playing a critical role in...
Real-world data from the US Flatiron Health Research Database demonstrate that most patients with HR-positive, HER2-negative early breast cancer remain on adjuvant abemaciclib at 6 months, with dosing strategies playing a critical role in...
Real-world data from the US...
03/24/2026
Oncology
News
Clinical and Molecular Factors Influence Outcomes of Sevabertinib in HER2-Mutated NSCLC
03/24/2026
Stephanie Holland
Results from an exploratory analysis of the phase 1/2 SOHO-01 study suggest that clinical and molecular characteristics may influence treatment outcomes among patients with HER2-mutated non-small cell lung cancer receiving sevabertinib.
Results from an exploratory analysis of the phase 1/2 SOHO-01 study suggest that clinical and molecular characteristics may influence treatment outcomes among patients with HER2-mutated non-small cell lung cancer receiving sevabertinib.
Results from an exploratory...
03/24/2026
Oncology
News
Pharmacist-Led Interventions Improve Medication Management for Patients Receiving Vorasidenib for Low-Grade Gliomas
03/24/2026
Stephanie Holland
Results from a retrospective, single-center study suggest that pharmacist-led interventions play a critical role in optimizing medication management among patients with low-grade gliomas receiving vorasidenib.
Results from a retrospective, single-center study suggest that pharmacist-led interventions play a critical role in optimizing medication management among patients with low-grade gliomas receiving vorasidenib.
Results from a retrospective,...
03/24/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use